View Full Version : NIH GUIDE

Daniel B. Sheffer
01-15-1992, 12:14 AM
The following announcement was published recently in the NIH Guide
V21(02) and might be of interest to the readers of biomch-l:

$$P5 BEGIN PA-92-34 *************************************************


PA: PA-92-34

P.T. 22, 34; K.W. 0715010, 0715136, 0715185, 0715026, 0710030, 0785055

National Institute of Arthritis and Musculoskeletal and Skin Diseases


The objective of this Program Announcement is to emphasize the
continuing commitment of the National Institute of Arthritis and
Musculoskeletal and Skin Diseases (NIAMS) to support the research
development of biomedical investigators who conduct research on the
basic biology, organ systems, and diseases and disorders within its
mandate. The NIAMS encourages all individuals, especially members of
underrepresented groups, to submit applications. The aim is to
increase the expertise and development of researchers in areas relevant
to the mission of the NIAMS.


The NIAMS encourages applications for individual fellowships and
research career awards. The research emphasis or thrust of such
applications must be related to the mission of the NIAMS. Major areas
of interest include:

o Arthritis and connective tissue diseases

o Bone biology and diseases

o Muscle biology and diseases

o Musculoskeletal diseases and disorders

o Skin biology and diseases

o Musculoskeletal fitness, exercise physiology and gait analysis

o Immunology and inflammatory processes related to diseases of
connective tissue, bone, muscle, and skin

o Epidemiology of arthritis, bone, muscle, and skin diseases

o Structure, function and physiology of bone, muscle, skin, joints,
and connective tissue

o Metabolism of muscle, bone, and skin


Due to the complexity of the tissues and diseases, it is becoming
increasingly clear that research excellence in arthritis, muscle
biology, musculoskeletal disorders, and bone and skin diseases requires
interdisciplinary approaches. Thus, the NIAMS encourages researchers
at appropriate stages in their careers to develop additional expertise
in areas such as molecular biology, cell biology, structural biology,
biophysics, immunology, developmental biology, genetics, and
epidemiology. Examples of multi-disciplinary approaches that are
relevant to the NIAMS include, but are not limited to, the following:

o The use of cell biology and molecular genetics to investigate the
regulation of growth and proliferation of muscle, bone, and skin cells;
extracellular controls (e.g., cytokines), receptors, extracellular
matrix, structural function;

o Immunology to investigate the basis of immune and autoimmune
mediated diseases of muscle, bone, joints, and skin.

o Membrane biochemistry, physiology, and molecular genetics to explore
the molecular basis of defective membrane channels and ion transport in
cells of muscle, bone, and skin;

o Structural biology and human genetics to investigate the development
or application of macromolecular X-ray diffraction and Nuclear Magnetic
Resonance methods, computer-assisted modeling, and molecular dynamics
or mechanical simulations to studies of enzyme function, molecular
biology, molecular genetics, and/or biochemical genetics of hereditary
diseases in model systems and humans;

o Wide bore and whole body magnetic resonance spectroscopy and imaging
of metabolic processes during rest and exercise, in normal or diseased


Several mechanisms exist that will support the professional development
of individuals who can advance research in these areas. Each mechanism
is tailored to a particular stage of the investigator's career. The
existing mechanisms are: Individual Fellowships (F32, F33); Physician
Scientist Award (PSA K11); Clinical Investigator Award (CIA K08); and
Research Career Development Award (RCDA K04). Physician investigators
are encouraged to use the PSA and CIA to develop expertise in basic and
clinical research.

A research training or career development program for a
physician-scientist should equip the individual to become an
independent investigator capable of designing and executing rigorous
research protocols carefully crafted to examine a hypothesis. Ideally,
such investigators should be able to integrate patient-oriented and
laboratory-oriented research methods to address questions related to
the physiology and pathophysiology of arthritis and muscle, bone, and
skin diseases and disorders.

Support mechanisms for training and research career development awards
are summarized in this announcement. Detailed guidelines for each of
the mechanisms may be obtained from the office of sponsored programs at
most research institutions and from the Division of Research Grants,
NIH, Westwood Building, Room 240, Bethesda, Maryland 20892, Phone,
(301) 496-7441. Only U.S. citizens and non-citizen nationals are
eligible for support under these programs.


Individual National Research Service Awards (NRSA) are given at the
postdoctoral level. The application must describe a specific research
project that is guided and sponsored by a preceptor. This support is
for full-time research training.

Provisions of these awards include:

o Awards for up to 36 months of training

o Stipends based on years of experience: range is $18,600-32,300 per

o Institutional allowance of $3,000 per year ($2,000 per year for
fellows at NIH) to help meet expenses;

o Support for more than 12 months requires "payback."


Senior fellowships are designed for experienced scientists who wish to
make major changes in the direction of their research career, to
broaden their research capabilities, or to enlarge their command of an
allied research field. Applicants for an F33 must hold a doctoral
degree or equivalent and show at least seven subsequent years of
relevant professional or research experience.

Provisions of the award include:

o Awards for up to 24 months;

o Stipend up to $32,300 per year.


Application receipt dates for these two awards are January 10, May 10,
and September 10. Applicants must use Fellowship Application Kit (PHS
416-1, Revised 4/89). Fellowships will be reviewed through the
accelerated NIH peer review system in the Division of Research Grants.
Earliest possible funding start dates will be seven to eight months
after receipt dates.

Fellowship applications submitted in response to this announcement must
be identified by typing PA-RESEARCH FELLOWSHIP AWARDS and PA-92-34 on
Item 3 of the face page, below the title of the project.


The Physician Scientist Award (PSA) is designed to encourage the newly
trained clinician to develop independent research skills and experience
in a fundamental science. The award is divided into two phases.
During Phase I, which may last two to three years, the candidate is
expected to develop independent research skills and experience in a
fundamental science. The primary sponsor must be an accomplished basic
science investigator. Phase II entails intensive research activity,
applying the skills learned during Phase I.

Applicants for the PSA must:

o Hold an M.D. or equivalent clinical degree. Generally, candidates
holding the Ph.D. are ineligible;

o Have completed at least one postgraduate year of clinical training
by the time of award;

o Not have previous independent research support.

Provisions of the PSA include:

o Five years of support, nonrenewable; durations of three or four
years may be requested at the time of application;

o Salary up to $50,000 per year plus fringe benefits;

o Up to $10,000 (Phase I) and $20,000 (Phase II) per year for research
supplies, equipment, technical assistance, travel;

o Commitment, as a minimum, of 75 percent time to PSA activities.


The Clinical Investigator Award (CIA) is offered to provide the
opportunity for promising clinically trained individuals with
demonstrated aptitude in research to develop as independent

Applicants for the CIA must:

o Hold an M.D. or other health professional degree;

o Have approximately four to eight years of postdoctoral experience,
both clinical and research (a minimum of two years of each) by the
projected start of the award;

o Not have been a Principal Investigator on a Public Health
Service-supported research project.

Provisions of the CIA include:

o Five years of support, nonrenewable; tenures of three or four years
may be requested at time of application;

o Salary up to $50,000 per year plus fringe benefits;

o Up to $20,000 per year for research supplies, equipment, technical
assistance, travel;

o Commitment, as a minimum, of 75 percent time to the project.


The Research Career Development Award (RCDA) provides salary support to
enhance the research capabilities of individuals in the formative
stages of their careers. Candidates who have demonstrated outstanding
potential as independent investigators in health-related research, but
need to be released from some of the teaching, clinical, and
administrative duties assigned to junior faculty, are eligible.

Applicants for the RCDA must:

o Hold a doctoral degree or equivalent, have usually at least five
years postdoctoral research experience, and be principal investigator
of a peer-reviewed research grant;

o Describe in the application how the award will enhance development
as an independent investigator;

o Have enough independent research support for the research proposed
in the RCDA application;

o Hold a faculty appointment.

Provisions of the RCDA include:

o Five years of support, nonrenewable;

o Salary up to $50,000 per year plus fringe benefits. No funds are
available under this award for research expenses. These expenses are
expected to be included in the independent research support described

o Commitment of at least 80 percent time to research. The remaining
time (up to 20 percent) must be spent on research-related activities
that will enhance research career development.

RCDA applications may be submitted concurrently with a traditional
research grant application but may not be submitted concurrently with
other development awards such as PSA, CIA, or First Independent
Research Support and Transition (FIRST) Award.


Application receipt dates for all career development awards (K series)
are February 1, June 1, and October 1. The PSA and CIA applications
will be reviewed by an appropriate review committee within a funding
Institute. RCDA applications will be reviewed by an initial review
group in the Division of Research Grants. Earliest possible funding
dates are approximately 10 months after the receipt dates. Use
application form PHS 398, Rev. 10/88 and 9/91, with special
instructions for the PSA, CIA, and RCDA ("The K Awards," October 1991)
available from the Office of Grants Inquiries.

Applications submitted in response to this announcement must be
identified by typing PA-RESEARCH CAREER AWARDS and PA-92-34 on line 2
of the face page, below the title of the project.

The typed original application and six signed exact single-sided
photocopies must be submitted or delivered to:

Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD 20892**

Applicants from institutions that have a General Clinical Research
Center (GCRC) funded by the NIH National Center for Research Resources
may identify the GCRC as a resource for conducting the proposed
activity. In such a case, a letter of agreement from either the GCRC
program director or Principal Investigator must be included with the


NIH and ADAMHA policy is that applicants for NIH/ADAMHA clinical
research grants and cooperative agreements will be required to include
minorities and women in study populations so that research findings can
be of benefit to all persons at risk of the disease, disorder or
condition under study; special emphasis should be placed on the need
for inclusion of minorities and women in studies of diseases, disorders
and conditions which disproportionately affect them. This policy is
intended to apply to males and females of all ages. If women or
minorities are excluded or inadequately represented in clinical
research, particularly in proposed population-based studies, a clear
compelling rationale should be provided.

The composition of the proposed study population must be described in
terms of gender and racial/ethnic group. In addition, gender and
racial/ethnic issues should be addressed in developing a research
design and sample size appropriate for the scientific objectives of the
study. This information should be included in the form PHS 398 in
Section 2, A-D of the Research Plan AND summarized in Section 2, E,
Human Subjects. Applicants/offerors are urged to assess carefully the
feasibility of including the broadest possible representation of
minority groups. However, NIH recognizes that it may not be feasible
or appropriate in all research projects to include representation of
the full array of United States racial/ethnic minority populations
(i.e., Native Americans (including American Indians or Alaskan
Natives), Asian/Pacific Islanders, Blacks, Hispanics).

The rationale for studies on single minority populations groups should
be provided.

For the purpose of this policy, clinical research includes human
biomedical and behavioral studies of etiology, epidemiology, prevention
(and preventive strategies), diagnosis, or treatment of diseases,
disorders or conditions, including but not limited to clinical trials.

The usual NIH policies concerning research on human subjects also
apply. Basic research or clinical studies in which human tissues
cannot be identified or linked to individuals are excluded. However,
every effort should be made to include human tissues from women and
racial/ethnic minorities when it is important to apply the results of
the study broadly, and this should be addressed by applicants.

For foreign awards, the policy on inclusion of women applies fully;
since the definition of minority differs in other countries, the
applicant must discuss the relevance of research involving foreign
population groups to the United States' population, including

If the required information is not contained within the application,
the application will be returned.

Peer reviewers will address specifically whether the research plan in
the application conforms to these policies. If the representation of
women or minorities in a study design is inadequate to answer the
scientific question(s) addressed AND the justification for the selected
study population is inadequate, it will be considered a scientific
weakness or deficiency in the study design and will be reflected in
assigning the priority score to the application.

All applications for clinical research submitted to NIH are required to
address these policies. NIH funding components will not award grants
or cooperative agreements that do not comply with these policies.


For further information about these awards, contact:

Richard W. Lymn, Ph.D.
Program Director
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Westwood Building, Room 403
Bethesda, MD 20892
Telephone: (301) 496-7495

For administrative and fiscal matters, contact:

Diane Watson
Grants Management Officer
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Westwood Building, Room 407-A
Bethesda, MD 20892
Telephone: (301) 496-7495


This program is described in the Catalog of Federal Domestic Assistance
No. 93.846, Arthritis, Musculoskeletal and Skin Diseases Research.
Awards will be made under the authority of the Public Health Service
Act, Title III, Section 301 (Public Law 78-410, as amended; 42 USC 241)
and administered under PHS grants policies and Federal Regulations 42
CFR Part 52 and Part 66 and 45 CFR Part 74. This program is not
subject to the intergovernmental review requirements of Executive Order
12372 or Health Systems Agency review.

================================================== ================
AKRON, OHIO 44325-0302 TELEFAX 216 374 8834
================================================== ================